Bayer Selects Genedata’s Bioinformatic Platform for its Target Research and Biomarker Activities

Genedata has announced the expansion of its collaboration with Bayer HealthCare to include multiple sites in Germany and the US. Genedata will deliver a software solution for characterizing targets and biomarkers.

"Genedata have helped resolve bottlenecks in our research processes, an achievement reflecting their sound grasp of drug discovery," says Professor Andreas Busch, Head of Global Drug Discovery, Bayer HealthCare.

The collaboration has expanded to complement the activities of Bayer HealthCare’s target and biomarker research program.

Biomarkers will help identify compounds likely to be effective at later drug development stages, enabling Bayer HealthCare to focus its attention on the most promising therapeutic leads.

"In addition to strong software functionality, we require scalability and solid result information management," explained Dr. Joe Catino, Head of Discovery US, Bayer Pharmaceuticals Corp. in West Haven.

Genedata’s solutions incorporate industry-standard database technologies with an advanced three tier client-server architecture.

This has facilitated efficient deployment and integration with Bayer HealthCare’s global research informatics infrastructure.

"We are delighted that Bayer HealthCare has chosen Genedata’s proven IT solutions to support its target and biomarker research efforts," says Dr. Othmar Pfannes, Chairman and President of Genedata.

Earlier phases of the collaboration have been expanded to create a global research informatics solution for Bayer Healthcare.

Dr. Pfannes added, "The collaboration demonstrates the usefulness of Genedata Expressionist^® and Genedata Phylosopher^® for target identification, diagnostics, toxicology and biomarker studies."